Ahead of Myriad (MYGN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Wall Street analysts expect Myriad Genetics (MYGN) to post quarterly loss of -$0.02 per share in its upcoming report, which indicates a year-over-year decline of 166.7%. Revenues are expected to be $207.59 million, down 1.4% from the year-ago quarter.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Before a company reveals its earnings, ...